MX2022004033A - Suministro transdermico de dronabinol. - Google Patents

Suministro transdermico de dronabinol.

Info

Publication number
MX2022004033A
MX2022004033A MX2022004033A MX2022004033A MX2022004033A MX 2022004033 A MX2022004033 A MX 2022004033A MX 2022004033 A MX2022004033 A MX 2022004033A MX 2022004033 A MX2022004033 A MX 2022004033A MX 2022004033 A MX2022004033 A MX 2022004033A
Authority
MX
Mexico
Prior art keywords
dronabinol
transdermal delivery
delivery system
transdermal
nausea
Prior art date
Application number
MX2022004033A
Other languages
English (en)
Inventor
Marina Borovinskaya
Nisarg Modi
Tamanna Lather
Fotios M Plakogiannis
Original Assignee
Starton Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starton Therapeutics Inc filed Critical Starton Therapeutics Inc
Publication of MX2022004033A publication Critical patent/MX2022004033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un sistema de suministro transdérmico de fármacos que comprende dronabinol. El sistema de suministro transdérmico de dronabinol proporciona una concentración en plasma de fármaco a una velocidad predeterminada durante un periodo de tiempo predeterminado, lo que ofrece un régimen terapéutico simplificado al disminuir la frecuencia de dosificación para el tratamiento y/o prevención de náuseas y/o vómitos asociados con, por ejemplo, la quimioterapia.
MX2022004033A 2019-10-03 2020-10-02 Suministro transdermico de dronabinol. MX2022004033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962910255P 2019-10-03 2019-10-03
PCT/US2020/054070 WO2021067806A1 (en) 2019-10-03 2020-10-02 Transdermal delivery of dronabinol

Publications (1)

Publication Number Publication Date
MX2022004033A true MX2022004033A (es) 2022-07-19

Family

ID=72964852

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004033A MX2022004033A (es) 2019-10-03 2020-10-02 Suministro transdermico de dronabinol.

Country Status (8)

Country Link
US (2) US20210100737A1 (es)
EP (1) EP4037663A1 (es)
JP (1) JP2022550569A (es)
CN (1) CN114650809A (es)
AU (1) AU2020358869A1 (es)
CA (1) CA3156257A1 (es)
MX (1) MX2022004033A (es)
WO (1) WO2021067806A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210236417A1 (en) * 2019-10-03 2021-08-05 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
CA3156257A1 (en) * 2019-10-03 2021-04-08 Starton Therapeutics, Inc. TRANSDERMAL DELIVERY OF DRONABINOL

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US5804592A (en) * 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US6503532B1 (en) 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
CN101175403A (zh) * 2005-05-13 2008-05-07 尤尼麦德制药公司 延迟性化疗引起的恶心和呕吐的屈大麻酚治疗
EP1881757A4 (en) * 2005-05-13 2008-09-10 Unimed Pharmaceuticals Inc DRONABINOL TREATMENT OF CHEMOTHERAPY-INDUCED POSSIBLE INCOMPATIBILITY AND ILLUSTRATION
WO2009158477A1 (en) * 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
US20210236417A1 (en) * 2019-10-03 2021-08-05 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
CA3156257A1 (en) * 2019-10-03 2021-04-08 Starton Therapeutics, Inc. TRANSDERMAL DELIVERY OF DRONABINOL

Also Published As

Publication number Publication date
AU2020358869A1 (en) 2022-04-14
EP4037663A1 (en) 2022-08-10
US20210220325A1 (en) 2021-07-22
JP2022550569A (ja) 2022-12-02
WO2021067806A1 (en) 2021-04-08
US20210100737A1 (en) 2021-04-08
CA3156257A1 (en) 2021-04-08
CN114650809A (zh) 2022-06-21

Similar Documents

Publication Publication Date Title
MX2022004258A (es) Entrega transdermica de cannabidiol.
MX2022004033A (es) Suministro transdermico de dronabinol.
MX2020010689A (es) Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
CR20210436A (es) Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales
MX2022013410A (es) Metodos de tratamiento.
WO2015017609A3 (en) Systems and methods for drug delivery, treatment, and monitoring
JOP20190281A1 (ar) مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
AU2017261355A1 (en) Apparatuses, methods, and systems for delivering medication using medication kits
MX2017012991A (es) Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito.
NZ769954A (en) Syringe devices for use in an emergency
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
MX2022015057A (es) Metodo para administracion pulsatil de un farmaco gaseoso.
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2022006786A (es) Método de tratamiento de cáncer mediante la administración de un agente terapéutico anti-pd-1 o anti-pd-l1 mediante un dispositivo de administración linfática.
MX2023002482A (es) Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2021014987A (es) Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.
MX2023011948A (es) Entrega transdermica de cannabidiol:.
MX2020008905A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
MX2021008329A (es) Farmaco profilactico o terapeutico para enfermedades neurodegenerativas.
MX2021004895A (es) Metodo de terapia de combinacion para tratar neoplasias mieloproliferativas con un conjugado de toxina de la difteria-interleucina humana 3 en combinacion con otros agentes.
MX2020013385A (es) Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.
MX2019003943A (es) Farmaco eficaz para un metodo linfogeno de administracion de farmaco.
ZA202201669B (en) Intrathecal administration of levetiracetam
UA90503U (uk) Спосіб лікування хронічної серцевої недостатності
UA99309U (ru) Способ лечения ретробульбарного неврита